View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 1, 2022

Aptinyx concludes enrolment in Phase IIb fibromyalgia therapy trial

The change in average daily pain scores from baseline to week 12 is the primary endpoint of the trial.

Aptinyx has concluded subject enrolment in its ongoing Phase IIb clinical trial of NYX-2925 for the treatment of patients with fibromyalgia. 

A total of 305 subjects were enrolled into the trial with results anticipated in the early to the mid third quarter of this year.

The double-blind, randomised, placebo-controlled trial is analysing the safety and efficacy of NYX-2925 in fibromyalgia patients. NYX-2925 is a new oral NMDA receptor positive allosteric modulator.

On concluding the screening period, eligible subjects are randomised to receive either once a day oral doses of 50mg or 100 mg NYX-2925 or placebo. 

Subjects who were enrolled recently are nearing completion of the 12-week treatment period and a safety follow-up for 30 days. 

The variation in average daily pain scores from baseline to week 12 as assessed on the ten-point numeric rating scale (NRS) will be the primary endpoint of the trial. 

The trial will also analyse various other secondary endpoints linked to fatigue, pain, cognitive performance and quality of life of the subject.

Aptinyx president and CEO Andy Kidd said: “Fibromyalgia is one of the most common chronic pain conditions and can severely impair quality of life and function for those who suffer from it. 

“Based on the results of our previous fibromyalgia study, in which NYX-2925 alleviated patients’ symptoms and improved biomarkers of centralized pain processing, we believe it has the potential to deliver meaningfully improved outcomes for fibromyalgia patients.”

A chronic condition, fibromyalgia is linked to widespread pain, tenderness and fatigue. 

NYX-2925 was found to possess activity that impacts central pain processing, offering reduction in pain and other symptoms linked to chronic pain conditions in clinical trials. 

Furthermore, the treatment was found to have a favourable safety and tolerability profile across various dose ranges in trials till date. 

In October last year, Aptinyx concluded subject enrolment in the Phase IIb trial of NYX-2925 for treating painful diabetic peripheral neuropathy.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy